Dolutegravir resistance in three pregnant and breastfeeding women in South Africa

Dolutegravir (DTG) has superior efficacy, safety, tolerability, and a better resistance profile compared with non-nucleoside reverse transcriptase inhibitors (NNRTI), making it the preferred antiretroviral therapy (ART) choice for adults and adolescents, including pregnant and breastfeeding women (PBFW)